Screener
Intellia Therapeutics NTLA Total Revenue
Total Revenue at other companies
Other financials
Where this comes from
Reported directly by Intellia Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Intellia Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337952
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Collaboration revenue | $7,659 | $14,245 | $22,707 | $30,872 |
| Operating expenses: | ||||
| Research and development | 82,595 | 97,035 | 163,332 | 205,462 |
| General and administrative | 37,824 | 27,206 | 72,667 | 56,213 |
| Total operating expenses | 120,419 | 124,241 | 235,999 | 261,675 |
| Operating loss | (112,760) | (109,996) | (213,292) | (230,803) |
| Other income, net: | ||||
| Interest income | 5,797 | 7,402 | 11,002 | 16,005 |
Item 1. Financial Statements
FAQ
- What is Intellia Therapeutics's total revenue?
- Intellia Therapeutics (NTLA) reported total revenue of $7.66M in Q2 2026.
- How has Intellia Therapeutics's total revenue changed year-over-year?
- Intellia Therapeutics's total revenue decreased by 46.2% year-over-year, from $14.25M to $7.66M.
- What is the long-term trend for Intellia Therapeutics's total revenue?
- Over 4 years (2021 to 2025), Intellia Therapeutics's total revenue has grown at a 19.6% compound annual growth rate (CAGR), from $33.05M to $67.67M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Intellia Therapeutics's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude